Clinical Utility of Beta-Blockers for Primary and Secondary Prevention of Coronary Artery Disease
Evaluation of: Bangalore S, Steg PG, Deedwania P et al. β-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA 308(13), 1340–1349 (2012).
The number of myocardial infarctions (MIs) in population remains high and this event is a significant predictor of mortality. Information in the literature points to a reduction in mortality, reinfarction and sudden death in first year, especially in patients with high risk, if β-blockers (BBs) are used after MI. In a perspective study, Zuckerman et al. have determined outcome following pharmacotherapy after acute MI in older adults. It is apparent that a number of matters require consideration in evaluation of the effectiveness of BBs. It seems that not all patients benefit equally from treatment with BBs but such an intervention reduces mortality. It is also important to recognize that the beneficial effects of BBs should not be considered in isolation since the biological system is too complex to manipulate with the use of a single class of drugs.
Calhoun, McKenzie L.; Cross, L. Brian; and Cooper-Dehoff, Rhonda M.. 2013. Clinical Utility of Beta-Blockers for Primary and Secondary Prevention of Coronary Artery Disease. Expert Review of Cardiovascular Therapy. Vol.11(3). 289-291. https://doi.org/10.1586/erc.13.16 ISSN: 1744-8344